MARKSANS PHARMA. Fact Sheet, MARKSANS PHARMA. Financial Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

MARKSANS PHARMA. Fact Sheet    (TCPH)


Going LIVE Today at 5pm: The EV Gold Rush Special Event


Here is the latest financial fact sheet of MARKSANS PHARMA.. For more details, see the MARKSANS PHARMA. quarterly results and MARKSANS PHARMA. share price and chart. For a sector overview, read our pharmaceuticals sector report.

MARKSANS PHARMA. Price History

Price Rs 59.0
Mkt Cap Rs m 24,129
Vol '000 222.4
P/E X 9.8
P/CF X 8.8
EPS (TTM) Rs 6.0
% ch % -1.3
No. of shares m 409.31
% ch week % 0.9
% ch 1-mth % -11.4
% ch 12-mth % -9.2
52 week H/L Rs 97.5/48.6
(As on Dec 7, 2021 03:26:00 PM)
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

MARKSANS PHARMA. Financials

No. of Mths
Year Ending
12
Mar-17
*
12
Mar-18
*
12
Mar-19
*
12
Mar-20
*
12
Mar-21
*
5-Yr Chart
Click to enlarge
MARKSANS PHARMA. EQUITY SHARE DATA
High Rs5858412766 
Low Rs3731221013 
Sales per share (Unadj.) Rs18.722.324.427.733.6 
Earnings per share (Unadj.) Rs0.30.92.03.05.8 
Diluted earnings per shareRs0.30.92.03.05.8 
Cash flow per share (Unadj.) Rs1.01.52.53.66.7 
Dividends per share (Unadj.) Rs0.050.050.050.100.25 
Adj. dividends per shareRs0.050.050.050.100.25 
Avg Dividend yield %0.10.10.20.50.6 
Book value per share (Unadj.) Rs10.611.513.315.521.7 
Adj. book value per shareRs10.611.513.315.521.7 
Shares outstanding (eoy) m409.31409.31409.31409.31409.31 
Bonus / Rights / Conversions  ----- 
Price / Sales ratio x2.52.01.30.71.2 
Avg P/E ratio x172.051.015.96.26.8 
P/CF ratio (eoy) x47.129.212.45.15.9 
Price / Book Value ratio x4.53.92.41.21.8 
Dividend payout %18.15.72.53.44.3 
Avg Mkt Cap Rs m19,49418,26612,8017,52116,188 
No. of employees `000NANANANANA 
Total wages/salary Rs m1,4971,4771,5911,6841,973 
Avg. sales/employee Rs ThNMNMNMNMNM 
Avg. wages/employee Rs ThNMNMNMNMNM 
Avg. net profit/employee Rs ThNMNMNMNMNM 
MARKSANS PHARMA. INCOME DATA
Net Sales Rs m7,6729,12710,00111,34213,762 
Other income Rs m1888546367 
Total revenues Rs m7,8609,21210,04711,34513,829 
Gross profit Rs m3297841,3211,9233,396 
Depreciation Rs m301268228267362 
Interest Rs m68102978780 
Profit before tax Rs m1494981,0431,5723,022 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m00000 
Tax Rs m36140239364636 
Profit after tax Rs m1133588041,2082,385 
Gross profit margin %4.38.613.217.024.7 
Effective tax rate %23.928.122.923.221.1 
Net profit margin %1.53.98.010.617.3 
MARKSANS PHARMA. BALANCE SHEET DATA
Current assets Rs m4,8394,4905,3145,9369,023 
Current liabilities Rs m2,9612,3312,3262,2882,984 
Net working cap to sales %24.523.729.932.243.9 
Current ratio x1.61.92.32.63.0 
Inventory Days Days00021 
Debtors Days Days118716478,313,06771,977,516 
Net fixed assets Rs m2,6792,8022,7103,0843,252 
Share capital Rs m409409409409409 
"Free" reserves Rs m3,9254,2995,0165,9518,456 
Net worth Rs m4,3344,7095,4256,3608,865 
Long term debt Rs m00000 
Total assets Rs m7,5187,2918,0259,02012,275 
Interest coverage x3.25.911.819.038.8 
Debt to equity ratio x00000 
Sales to assets ratio x1.01.31.21.31.1 
Return on assets %2.46.311.214.420.1 
Return on equity %2.67.614.819.026.9 
Return on capital %5.012.721.026.135.0 
Exports to sales %00000 
Imports to sales %1.84.73.35.27.4 
Exports (fob) Rs m00000 
Imports (cif) Rs m1424313315861,014 
Fx inflow Rs m2,0612,8144,0874,2665,874 
Fx outflow Rs m2115144717371,014 
Net fx Rs m1,8502,3003,6163,5294,860 
MARKSANS PHARMA. CASH FLOW
From Operations Rs m 141 589 274 2,333 1,787 
From Investments Rs m -207 -388 -135 -596 -449 
From Financial Activity Rs m -35 -54 -208 -1,136 -153 
Net Cashflow Rs m -101 147 -69 602 1,186 
* Results Consolidated
Source: Accord Fintech, Equitymaster

Share Holding

Promoters 48.3%
Institution 3.2%
Non-Institution 48.6%
Total 100.0%
Free Float 51.8%
Pledged promoter holdings 0.0%
 

Company Information

REGD OFF 11th Floor " Grandeur, Opp. Gundecha Symphony Veera Desai Extension Road, Oshiwara Andheri (W), Mumbai - 400053
E-MAIL info@marksanspharma.com WEB www.marksanspharma.com
TEL 022- 40012000 FAX 022- 40012011/40012099
SECTOR PHARMACEUTICALS GROUP Private sector
TR AGENT Bigshare Services Pvt Ltd, Bharat Tin Works Building, 1st floor Opp. Vasant Oasis, Andheri (E)
YEAR OF INC: 1992 BSE CODE: 524404 FV (Rs): 1 DIV YIELD (%): 0.4

Read: MARKSANS PHARMA. 2020-21 Annual Report Analysis

More Pharmaceuticals Company Fact Sheets:   AUROBINDO PHARMA  GLENMARK PHARMA  GRANULES INDIA  LAURUS LABS   SUN PHARMA  

Compare MARKSANS PHARMA. With:   AUROBINDO PHARMA  GLENMARK PHARMA  GRANULES INDIA  LAURUS LABS   SUN PHARMA  




Today's Market

Sensex Jumps 550 Points, Nifty Above 17,000; Metal & Banking Stocks Rally(10:30 am)

Asian stock markets are higher today as investors took heart from strong rebounds on Wall Street on hopes that the newest coronavirus variant will prove less virulent than earlier strains.

Views on news

MARKSANS PHARMA. 2020-21 Annual Report Analysis (Annual Result Update)

Nov 9, 2021 | Updated on Nov 9, 2021

Here's an analysis of the annual report of MARKSANS PHARMA. for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of MARKSANS PHARMA.. Also includes updates on the valuation of MARKSANS PHARMA..

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

India's Top 5 Monopoly Stocks to Watch Out for (Views On News)

Nov 30, 2021

These 5 companies dominate their sectors with a huge piece of the pie.

The Biggest Winners and Losers in India's Transition to Electric Vehicles (Profit Hunter)

Nov 26, 2021

How India's EV transition could be a major headwind for the incumbents.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK MARKSANS PHARMA.

  • Track your investment in MARKSANS PHARMA. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON MARKSANS PHARMA.

MARKSANS PHARMA. - MYLAN COMPARISON

COMPARE MARKSANS PHARMA. WITH

MARKET STATS